319 related articles for article (PubMed ID: 22454596)
1. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.
Rusnati M; Bugatti A; Mitola S; Leali D; Bergese P; Depero LE; Presta M
Sensors (Basel); 2009; 9(8):6471-503. PubMed ID: 22454596
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
[TBL] [Abstract][Full Text] [Related]
3. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
5. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.
Leali D; Inforzato A; Ronca R; Bianchi R; Belleri M; Coltrini D; Di Salle E; Sironi M; Norata GD; Bottazzi B; Garlanda C; Day AJ; Presta M
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):696-703. PubMed ID: 22267482
[TBL] [Abstract][Full Text] [Related]
6. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
[TBL] [Abstract][Full Text] [Related]
7. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G
Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023
[TBL] [Abstract][Full Text] [Related]
8. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
[TBL] [Abstract][Full Text] [Related]
9. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization.
Rusnati M; Presta M
Int J Clin Lab Res; 1996; 26(1):15-23. PubMed ID: 8739851
[TBL] [Abstract][Full Text] [Related]
10. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
[TBL] [Abstract][Full Text] [Related]
11. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
Rusnati M; Camozzi M; Moroni E; Bottazzi B; Peri G; Indraccolo S; Amadori A; Mantovani A; Presta M
Blood; 2004 Jul; 104(1):92-9. PubMed ID: 15031207
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
Leali D; Belleri M; Urbinati C; Coltrini D; Oreste P; Zoppetti G; Ribatti D; Rusnati M; Presta M
J Biol Chem; 2001 Oct; 276(41):37900-8. PubMed ID: 11473122
[TBL] [Abstract][Full Text] [Related]
13. N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors.
Nawaz IM; Chiodelli P; Rezzola S; Paganini G; Corsini M; Lodola A; Di Ianni A; Mor M; Presta M
Angiogenesis; 2018 Feb; 21(1):47-59. PubMed ID: 29030736
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1.
Ronca R; Benzoni P; Leali D; Urbinati C; Belleri M; Corsini M; Alessi P; Coltrini D; Calza S; Presta M; Dell'Era P
Mol Cancer Ther; 2010 Dec; 9(12):3244-53. PubMed ID: 20940322
[TBL] [Abstract][Full Text] [Related]
16. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
[TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.
Rusnati M; Urbinati C; Bonifacio S; Presta M; Taraboletti G
Pharmaceuticals (Basel); 2010 Apr; 3(4):1241-1278. PubMed ID: 27713299
[TBL] [Abstract][Full Text] [Related]
19. The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist.
Liekens S; Bronckaers A; Belleri M; Bugatti A; Sienaert R; Ribatti D; Nico B; Gigante A; Casanova E; Opdenakker G; Pérez-Pérez MJ; Balzarini J; Presta M
Mol Cancer Ther; 2012 Apr; 11(4):817-29. PubMed ID: 22302099
[TBL] [Abstract][Full Text] [Related]
20. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors.
Casu B; Guerrini M; Naggi A; Perez M; Torri G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
Biochemistry; 2002 Aug; 41(33):10519-28. PubMed ID: 12173939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
